In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma

Leukemia Research

Volumn 36, Issue 5, 2012, Pages 598-600

  Kim, Young ^a   Gast, Sanna Marie ^a   Endo, Tomoyuki ^b,c   Lu, Desheng ^b   Carson, Dennis ^b   Schmidt Wolf, Ingo G H ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Beta catenin; Lenalidomide; Lymphoma; Myeloma; Signal transduction; Wnt pathway

Indexed keywords

BETA CATENIN; ETACRYNIC ACID; LENALIDOMIDE; LYMPHOID ENHANCER FACTOR 1; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; FEMALE; IN VIVO STUDY; INTRACELLULAR SIGNALING; LOW DRUG DOSE; MONOTHERAPY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR VOLUME; WNT SIGNALING PATHWAY;

ANIMALS; BETA CATENIN; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DIURETICS; DRUG THERAPY, COMBINATION; ETHACRYNIC ACID; HUMANS; MICE; MICE, INBRED BALB C; MULTIPLE MYELOMA; THALIDOMIDE; WNT SIGNALING PATHWAY;

EID: 84862786059     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.01.025     Document Type: Article

References (8)

1. Willert K., Jones K.A. Wnt signaling: is the party in the nucleus?. Genes Dev 2006, 20:1394-1404.
2. Lu D., Zhao Y., Tawatao R., et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci 2004, 101:3118-3123.
3. Lu D., Liu J.X., Endo T., et al. Ethacrynic acid exhibits selective cytotoxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway. PLoS One 2009, 4(12):e8294.
4. Schmidt M., Sievers E., Endo T., et al. Targeting Wnt pathway in lymphoma and myeloma cells. Br J Haematol 2009, 144(5):796-798.
5. Kim Y., Alpmann P., Blaum-Feder S., et al. In vivo efficacy of griseofulvin against multiple myeloma. Leuk Res 2011, 35:1070-1073.
6. Schmidt M., Kim Y., Gast S.-M., et al. Increased in vivo efficacy of lenalidomide and thalidomide by addition of ethacrynic acid. In Vivo 2011, 25:325-333.
7. Kim Y., Alpmann P., Blaum-Feder S., et al. Increased in vivo efficacy of lenalidomide by addition of piroctone olamine. In Vivo 2011, 25(1):99-103.
8. Sukhdeo K., Mani M., Zhang Y., et al. Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci USA 2007, 104(18):7516-7521.